Stocksigma LogoStocksigma Logo

Alivus Life Sciences Q2FY27 Results: Record Margins and Strong Profit Growth

Alivus Life Sciences reported Q2FY27 revenue of Rs 6,820 Mn, up 16.0% YoY, led by a 20.8% YoY rise in non-GPL business

Alivus Life Sciences Q2FY27 Results: Record Margins and Strong Profit Growth

Alivus Life Sciences Ltd 路 Press Release 路 30 Oct 2026, 1:03 am

Alivus Life Sciences Q2FY27 Results: Record Margins and Strong Profit Growth Alivus Life Sciences reported Q2FY27 revenue of Rs 6,820 Mn, up 16.0% YoY, led by a 20.8% YoY rise in non-GPL business. EBITDA surged 47.0% YoY to Rs 2,851 Mn with record margins of 41.8% (up 880 bps YoY, 520 bps QoQ), driven by operating leverage and favorable product mix. PAT rose 51.3% YoY to Rs 1,968 Mn. As of 30th Sep'26, cash and equivalents stood at Rs 10,116 Mn. Solapur capex remains on track for completion across Q3-Q4FY27.

Original exchange filing (PDF)

More announcements from Alivus Life Sciences Ltd

All Alivus Life Sciences Ltd announcements